[ad_1]
There are currently around 70 pharmaceutical companies worldwide seeking to produce a vaccine against Covid-19. That Chinese companies have the greatest advance They are currently experimenting with humans in the second phase. There are also German manufacturing companies and England announced that they are experimenting with people in the first phase.
The company in the United States The company, Johnson & Johnson, has announced progress in the development of the Covid-19 vaccine. That there are plans to experiment with humans this September. And he points out that this vaccine is ready for emergency use early next year.
Dr. Paul Stoffel, Executive Vice President And the company’s chief scientific officer, Johnson & Johnson, said that the development of the cowavid vaccine began the first project in January. It is considered as a complete process, which is considered a fast operation compared to the development of conventional vaccines. Considered a challenge Because having to work quickly with There must be great caution in the process of human experimentation.
“The difficulty with producing this vaccine compared to the flu vaccine is that there is a more intense time.” Compared to the general process of vaccine development. But there are still advantages that The World Health Organization (WHO) has not reported that There are observed mutations in the virus. Which will lead to changes in vaccine development methods. On the contrary. Influenza viruses continually evolve. Therefore, the Global Influenza Surveillance and Response System (GISR) of the World Health Organization must monitor the influenza virus that can be transmitted between humans. Continue and improve the composition of the influenza vaccine twice a year ”
Dr. Paul Stoffel also said that for Johnson. The development of the COVID-19 vaccine is an extension of Jansen’s AdVac® and PER.C6® certified technologies. That this technology has the ability to rapidly develop new vaccine options, while increasing the production of selected vaccines at the same time. This technology was used to produce Ebola vaccines and create vaccines that were selected to fight Zika R.V and HIV, currently in phase two or phase three clinical development phase.
For the development of the Covid vaccine, the company spends more than $ 1 billion invested in research and development and plans to expand its production worldwide, with the expected production of more than one billion doses worldwide. And if this vaccine works, it will be delivered to those who need it immediately. And the company plans to establish a new production in the United States, Europe and / or Asia.
“We plan to start production and strive to bring the vaccine to the public at a reasonable, non-profit price because we have the PER.C6® technology to make the production system worthwhile.” For the production of vaccines and monoclonal antibodies with high performance. For the production of large quantities of vaccines. In a quick time To use in this emergency epidemic AND this vaccine will be delivered to all the countries in need around the world, whether in Asia. It certainly includes new countries, “said Dr. Paul Stoffel.
[ad_2]
